Leishmaniasis is a parasitic disease caused by protozoa of the genus Leishmania, which belong to the Trypanosomidae family. The disease is primarily transmitted through the bite of infected sand flies, which act as vectors for the parasite. There are several forms of leishmaniasis, the most common being cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL). Cutaneous leishmaniasis results in skin lesions, while visceral leishmaniasis affects internal organs such as the spleen, liver, and bone marrow. Global estimates suggest that approximately 1.5 million new cases of cutaneous leishmaniasis and 500,000 new cases of visceral leishmaniasis occur annually.
Clinical Manifestations
Cutaneous leishmaniasis typically manifests as one or more skin sores that may change in size and appearance over time. These lesions often resemble a “volcano” shape, with a raised edge and central crater, and are sometimes covered by a scab. The sores may be painful or painless, and some individuals may develop swollen lymph nodes near the affected area. In more severe cases, particularly when left untreated, the infection can cause mucosal leishmaniasis, a form that affects the mucous membranes, including the nose and mouth.
In contrast, visceral leishmaniasis usually presents with systemic symptoms such as fever, significant weight loss, and enlargement of the spleen and liver. Blood tests commonly reveal abnormal findings, including anemia, leukopenia, and thrombocytopenia. Without treatment, visceral leishmaniasis can be fatal, emphasizing the importance of timely diagnosis and intervention.
Geographic Distribution and Risk Factors
Leishmaniasis is endemic in parts of around 88 countries, primarily in the tropical and subtropical regions of the world. It is not found in Oceania or Australia, and most cases are concentrated in countries across Asia, the Middle East, Africa, and parts of Central and South America. For instance, more than 90% of cases of visceral leishmaniasis occur in India, Bangladesh, Nepal, Sudan, and Brazil. The disease is particularly prevalent in rural areas, though cases can also occur on the outskirts of urban centers. Sand flies, which are active primarily from dusk to dawn, are the primary vectors of the disease. They transmit the parasite when they bite an infected host, such as a rodent, dog, or human. Sand flies are difficult to detect due to their small size and their tendency to fly silently.
Certain groups are at higher risk for leishmaniasis, including adventure travelers, military personnel, Peace Corps volunteers, researchers, and individuals living in or traveling to endemic regions. The disease is most commonly transmitted during outdoor activities in the evening or night, when sand flies are most active.
Transmission and Prevention
Leishmaniasis is spread by the bite of infected phlebotomine sand flies. The primary means of transmission is through the bite of a female sand fly that has previously fed on an infected animal or human. Although rare, leishmaniasis can also be transmitted through blood transfusions, contaminated needles, or from a pregnant woman to her fetus. To prevent leishmaniasis, it is crucial to minimize exposure to sand fly bites. Current preventive measures focus on reducing the likelihood of bites, as no vaccine or specific drug for prophylaxis exists.
Key preventive strategies include:
Staying in well-screened or air-conditioned accommodations to limit exposure.
Wearing protective clothing, such as long sleeves, pants, and socks, to cover exposed skin.
Applying insect repellents containing DEET (N,N-diethyl-m-toluamide) to exposed skin, with recommended concentrations ranging from 30% to 35% for adults and lower concentrations for children.
Using permethrin-treated clothing and bed nets, which provide long-lasting protection against sand flies.
Avoiding outdoor activities, especially between dusk and dawn when sand flies are most active.
Diagnosis and Treatment
The diagnosis of leishmaniasis is confirmed through clinical evaluation and laboratory tests, including skin scrapings, biopsies, and serological tests. For cutaneous leishmaniasis, biopsy or molecular techniques such as polymerase chain reaction (PCR) may be employed to identify the parasite. In contrast, visceral leishmaniasis requires more extensive testing, including blood tests, bone marrow aspiration, and imaging studies to assess organ involvement.
Treatment varies depending on the form and severity of the disease. Localized cutaneous leishmaniasis can often be treated with intralesional injection of antimonials, such as sodium stibogluconate, or other topical therapies. Additional treatments include cryotherapy, electrosurgery, and excision for small lesions . Systemic treatment may be required for more extensive or visceral forms of leishmaniasis and typically involves the use of liposomal amphotericin B, miltefosine, or paromomycin. These systemic therapies are often administered under the supervision of an infectious disease specialist, particularly in severe cases, to avoid complications.
Newer treatment options, such as topical imiquimod and oral miltefosine, are being investigated for their effectiveness and convenience in treating leishmaniasis. These treatments offer potential benefits, especially in cases of cutaneous leishmaniasis, where localized therapy is often sufficient.
Conclusion
Leishmaniasis is a complex parasitic infection that manifests in various forms, with cutaneous and visceral leishmaniasis being the most common. While the disease is largely confined to specific geographical regions, it remains a significant public health concern due to its morbidity and potential for mortality if untreated. Prevention through vector control and protective measures is critical, as vaccines and prophylactic drugs are not yet available. Current treatments are effective but may require specialized care, particularly for visceral leishmaniasis. Ongoing research into novel therapeutic options and vaccines may offer new hope for managing and controlling leishmaniasis in the future.
References
Alvar, J., Vélez, I. D., Bern, C., & Herrero, M. (2020). The epidemiology and clinical management of leishmaniasis in Latin America. Journal of Global Health, 10(1), 010401. https://doi.org/10.7189/jogh.10.010401
Ameen, M. (2023). Cutaneous leishmaniasis: Clinical features, diagnosis, and treatment. Journal of the American Academy of Dermatology, 88(2), 455-465. https://doi.org/10.1016/j.jaad.2022.06.115
Centers for Disease Control and Prevention (CDC). (2022). Leishmaniasis: Prevention. Retrieved from https://www.cdc.gov/leishmaniasis/prevention.html
Desjeux, P. (2022). Leishmaniasis: Current status of epidemiology and future directions. Transactions of the Royal Society of Tropical Medicine and Hygiene, 116(4), 313-320. https://doi.org/10.1093/trstmh/trab046
Khan, M. A., Hashmi, M., & Khan, M. T. (2022). Mucosal leishmaniasis: A rare complication of cutaneous leishmaniasis. Clinical Infectious Diseases, 74(7), 1198-1201. https://doi.org/10.1093/cid/ciab674
Lima, J. M., Soares, P. M., & Santos, D. G. (2022). Advances in the treatment of cutaneous leishmaniasis. International Journal of Dermatology, 61(8), 1052-1061. https://doi.org/10.1111/ijd.16198
Oliva, G., Alvar, J., & Moreno, J. (2022). Treatment of visceral leishmaniasis: Current options and new approaches. Lancet Infectious Diseases, 22(1), 32-42. https://doi.org/10.1016/S1473-3099(21)00379-1
Singh, S., Kumar, A., & Rijal, S. (2021). Clinical features and diagnostic strategies for visceral leishmaniasis: A global perspective. Journal of Clinical Microbiology, 59(4), 45-56. https://doi.org/10.1128/JCM.02434-20
World Health Organization (WHO). (2023). Leishmaniasis. Retrieved from https://www.who.int/news-room/fact-sheets/detail/leishmaniasis
Zhu, X., Li, Y., & Wei, S. (2023). Novel therapeutic approaches for cutaneous leishmaniasis: Imiquimod and miltefosine. Antimicrobial Agents and Chemotherapy, 67(5), 1130-1138. https://doi.org/10.1128/AAC.02398-22
